Focused ultrasound-mediated disruption of blood plasma protein binding with pharmacological molecules
Focused ultrasound-mediated disruption of blood plasma protein binding with pharmacological molecules
批准号:
10046533
负责人:
Wonhye Lee
金额:
$52.69万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-01 至 2023-06-30
关键词:
AcousticsAddressAffinityAlbuminsAnimalsAnticonvulsantsAntiepileptic AgentsAreaBehaviorBehavioralBindingBinding ProteinsBiologicalBloodBlood - brain barrier anatomyBlood CirculationBlood VesselsBrainBrain regionCaliberCentral Nervous System AgentsCentral Nervous System DiseasesChronicDevicesDoseDrug Delivery SystemsElectroencephalographyElectrostaticsEnsureEpilepsyExhibitsFocused UltrasoundFrequenciesFutureGelGoalsHippocampus (Brain)HistologicImmunohistochemistryInjectionsIpsilateralKainic AcidMeasuresMediatingMethodsMolecularMonitorNeurologicPartial EpilepsiesPharmaceutical PreparationsPharmacologic ActionsPharmacological TreatmentPharmacologyPhenytoinPhysiologic pulsePlasmaPlasma ProteinsPropertyProteinsProtocols documentationRattusRecurrenceResearchRodentSafetySeizuresSerum AlbuminSerum ProteinsSonicationSprague-Dawley RatsTechniquesTemporal Lobe EpilepsyTestingTherapeuticTissuesUltrasonographyWireless Technologyaqueousblood-brain barrier disruptionbrain parenchymabrain tissuechemical bondchemical propertycombinatorialcraniumdesignexperimental groupexperimental studyflexibilityin vivomacromoleculemillimeternovelpressureuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Region-specific enhancement of drug delivery to the brain, without increasing systemic drug dose or actively
disrupting the blood-brain barrier, has been sought after for effective pharmacological treatment of various
central nervous system disorders. Among different approaches, we propose to enhance the delivery by
unbinding the drug from the plasma proteins to increase the local drug concentration that may be transported
across the vasculature. The overarching goal of our research is to examine the effects of transcranial focused
ultrasound (FUS) on region-specific disruption of plasma protein binding (PPB) with phenytoin (PHT) and to
evaluate if the regional increase of parenchymal PHT uptake results in the suppression of temporal lobe
epilepsy (TLE) in rodents. First, FUS will be noninvasively applied to an ipsilateral hippocampal area of non-
epileptic Sprague-Dawley rats receiving a therapeutic dose of PHT, using varying duty cycles, pulse durations,
and intensities of sonication. The parenchymal PHT uptake will be quantified using anti-PHT
immunohistochemistry, and the FUS parameter that results in the highest uptake level will be identified. Then,
using the parameter, multiple sessions of FUS will be applied to the epileptic brain region of chronic TLE rats
receiving daily therapeutic doses of PHT. Electroencephalography (EEG) will be acquired from the animals
using a wearable wireless EEG device and the frequency/duration of behavioral seizures and epileptographic
EEG will be quantified. These measures will be compared among four combinatorial experimental groups of
FUS(+/-) and PHT(+/-) to examine if the increased delivery of PHT, mediated by FUS, will enhance its anti-
convulsant effects. The animals, both epileptic and non-epileptic, will be evaluated for potential tissue or
vascular damage using histological analysis and for the presence of undesired disruption of the blood-brain
barrier. The proposed method of acoustic disruption of PHT-PPB may provide an elegant and unprecedented
option for suppressing seizure activity associated with focal epilepsy. Similar FUS protocols may also be
applicable to increase regional delivery of a wide range of drugs that have high affinity to plasma proteins.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金